Title
Early restaging positron emission tomography with <tex>$^{18}F$</tex>-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma Early restaging positron emission tomography with <tex>$^{18}F$</tex>-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Publication type
article
Publication
Amsterdam ,
Subject
Human medicine
Source (journal)
Annals of oncology / European Society for Medical Oncology. - Amsterdam
Volume/pages
13(2002) :9 , p. 1356-1363
ISSN
0923-7534
ISI
000178069500010
Carrier
E
Target language
English (eng)
Full text (Publishers DOI)
Abstract
Background: Less than half of all patients with aggressive non-Hodgkins lymphoma (NHL) are cured with standard chemotherapy. Therefore, it is important to distinguish between responders to standard treatment and non-responders who may benefit from an early change to a more effective therapy. This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL. Patients and methods: Seventy newly diagnosed patients with aggressive NHL, who were treated with doxorubicin-containing chemotherapy, underwent a [18F]FDG-PET scan at midtreatment. Presence or absence of abnormal [18F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using KaplanMeier survival analysis. Multivariate analysis was performed to evaluate the effect of the International Prognostic Index (IPI) and early [18F]FDG-PET findings on PFS and OS. Results: At midtreatment, 33 patients showed persistent abnormal [18F]FDG uptake and none of these patients achieved a durable complete remission (CR), whereas 37 patients showed a negative scan; 31/37 remained in CR, with a median follow-up of 1107 days. Only 6/37 patients either achieved a partial response or relapsed. Comparison between groups indicated a statistically significant association between [18F]FDG-PET findings and PFS (P <1 × 105) and OS (P <1 × 105). In multivariate analysis, [18F]FDG-PET at midtreatment was a stronger prognostic factor for PFS (P <1 × 107) and OS (P <9 × 106) than the IPI (P <0.11 and P <0.03, respectively). Conclusions: Early restaging [18F]FDG-PET may be used to tailor induction chemotherapy in patients with aggressive NHL.
E-info
https://repository.uantwerpen.be/docman/iruaauth/efa133/3e21e1ff4f7.pdf
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000178069500010&DestLinkType=RelatedRecords&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000178069500010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000178069500010&DestLinkType=CitingArticles&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848